收购司法鉴定技术公司连续三年商誉减值，国发股份被问询

Core Viewpoint - The company, Guofa Co., Ltd. (国发股份), is facing significant financial challenges due to the underperformance of its acquired subsidiary, Gaoshen Biotechnology, leading to substantial goodwill impairment over three consecutive years [1][2]. Financial Performance - For the fiscal year 2025, Guofa Co. anticipates a revenue of approximately 330 million yuan and a net loss attributable to shareholders of around 85 million yuan, with a non-recurring net loss of about 85.5 million yuan [1]. - The company has reported goodwill impairment provisions of 55 million yuan and 60 million yuan for the years 2023 and 2024, respectively, with an expected provision of about 65 million yuan for 2025 [2]. Acquisition and Goodwill Impairment - Guofa Co. acquired a 99.9779% stake in Gaoshen Biotechnology for approximately 355.69 million yuan in 2020, entering the molecular diagnostics and forensic identification business [1]. - The actual performance of Gaoshen Biotechnology from 2023 to 2025 has significantly deviated from initial profit forecasts, with revenue realization rates between 42.25% and 50.35% [2][3]. Market Conditions and Challenges - The decline in Gaoshen's performance is attributed to reduced customer demand, budget cuts from public security clients, and a decrease in successful bids for projects [3][4]. - In 2023, Gaoshen's bid amounts dropped from 110.21 million yuan in 2022 to 68.13 million yuan, a decrease of 38.19% [4]. Industry Trends - The overall industry is experiencing a downward trend in revenue, with comparable companies showing median revenue declines of 24.23%, 9.74%, and 17.44% for the years 2023 to 2025 [4]. - Guofa Co. acknowledges that the future value of goodwill is highly dependent on Gaoshen's ability to meet expected revenue and profit growth, which is threatened by market competition and other external factors [5].